EFEva Fellinger

Eva Fellinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eva Fellinger has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Selective and Fast Cortisol Sensing in Human Saliva Using Graphene‐Based On‐Chip Field‐Effect Transistors

    by Bajramshahe Shkodra, Ksenija Arslanova, Eva Fellinger, Tanja Stimpel‐Lindner, Sebastian Klenk, Sebastian Hauk, Kathrin C. Knirsch, Andreas Hirsch, Kristiina Iljin, Tarja K. Nevanen, et al.

    Monitoring of biomarkers in body fluids is highly sought after for medical diagnostics and tracking health conditions. Conventional analytical methods require centralized facilities and complex protocols, limiting applicability for real‐time or point‐of‐care use. In recent years, graphene‐based transducers have shown high potential for miniaturized biosensing, however they have so far been hardly tested in real‐case scenarios. In this work, electrolyte‐gated graphene field‐effect transistors (EG‐GFETs) are developed for the detection of the primary stress hormone cortisol in human saliva. The sensor consists of chemical vapor deposition (CVD)‐grown graphene functionalized with perylene bisimide (PBI) linkers for immobilizing anticortisol (17) Fab fragments. Cortisol is detected over a dynamic range from 100 fM to 1 μM, covering physiologically relevant concentration ranges. The measurements show high correlation with enzyme‐linked immunosorbent assay (ELISA) tests performed in parallel on the same samples. The immediate, label‐free sensing of biomarkers in human saliva represents a major advance in miniaturized biosensing and can potentially be extended to further analytes and integrated portable monitoring units.

  • Open Access

    Virtual stress testing: Analyzing endocrine, metabolic, cardiovascular, and psychological responses to the TSST-VR

    by Eva Fellinger, Tom Brandt, Andrea Schittenhelm, Eric Quarg, Matthias Pröll, Gregor Domes, Annette Schmidt


  • Open Access

    Analytical Performance of the FreeStyle Libre 2 Glucose Sensor in Healthy Male Adults

    by Eva Fellinger, Tom Brandt, Justin Creutzburg, Tessa Rommerskirchen, Annette Schmidt

    Continuous Glucose Monitoring (CGM) not only can be used for glycemic control in chronic diseases (e.g., diabetes), but is increasingly being utilized by individuals and athletes to monitor fluctuations in training and everyday life. However, it is not clear how accurately CGM reflects plasma glucose concentration in a healthy population in the absence of chronic diseases. In an oral glucose tolerance test (OGTT) with forty-four healthy male subjects (25.5 ± 4.5 years), the interstitial fluid glucose (ISFG) concentration obtained by a CGM sensor was compared against finger-prick capillary plasma glucose (CPG) concentration at fasting baseline (T0) and 30 (T30), 60 (T60), 90 (T90), and 120 (T120) min post OGTT to investigate differences in measurement accuracy. The overall mean absolute relative difference (MARD) was 12.9% (95%-CI: 11.8–14.0%). Approximately 100% of the ISFG values were within zones A and B in the Consensus Error Grid, indicating clinical accuracy. A paired t-test revealed statistically significant differences between CPG and ISFG at all time points (T0: 97.3 mg/dL vs. 89.7 mg/dL, T30: 159.9 mg/dL vs. 144.3 mg/dL, T60: 134.8 mg/dL vs. 126.2 mg/dL, T90: 113.7 mg/dL vs. 99.3 mg/dL, and T120: 91.8 mg/dL vs. 82.6 mg/dL; p < 0.001) with medium to large effect sizes (d = 0.57–1.02) and with ISFG systematically under-reporting the reference system CPG. CGM sensors provide a convenient and reliable method for monitoring blood glucose in the everyday lives of healthy adults. Nonetheless, their use in clinical settings wherein implications are drawn from CGM readings should be handled carefully.